CADTH | Evidence Driven
CADTH | Evidence Driven

Search CADTH

Filters

No filters applied.

Showing 21 - 30 results of 3649

Download as CSV

Everolimus (Afinitor) (Last Updated: Mar 19, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Afinitor
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Subependymal giant cell astrocytoma associated with tuberous sclerosis complex

Icatibant (Firazyr) (Last Updated: Mar 4, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Firazyr
Manufacturer:
Shire Human Genetic Therapies (Canada) Inc.
Submission Type:
Initial
Indications:

Angioedema, hereditary

Tocilizumab (Actemra) (Last Updated: Feb 23, 2015)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Actemra
Manufacturer:
Hoffmann-La Roche Limited
Submission Type:
Initial
Indications:

Arthritis, Rheumatoid

Pasireotide diaspartate (Signifor) (Last Updated: Feb 27, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Signifor
Manufacturer:
Novartis Pharmaceuticals Inc.
Submission Type:
Initial
Indications:

Cushing’s Disease

Ranibizumab (Lucentis) (Last Updated: Feb 28, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Lucentis
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Choroidal neovascularisation, myopic

Umeclidinium/vilanterol (Anoro Ellipta) (Last Updated: Feb 26, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Anoro Ellipta
Manufacturer:
GlaxoSmithKline Inc.
Submission Type:
Initial
Indications:

Chronic Obstructive Pulmonary Disease

Indacaterol/glycopyrronium (Ultibro Breezhaler) (Last Updated: Feb 3, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Ultibro Breezhaler
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

COPD

Alogliptin (Nesina) (Last Updated: Jan 30, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Nesina
Manufacturer:
Takeda Canada Inc.
Submission Type:
Initial
Indications:

Diabetes mellitus (Type 2)

Macitentan (Opsumit) (Last Updated: Dec 18, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Opsumit
Manufacturer:
Actelion Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Pulmonary arterial hypertension

Aripiprazole (Abilify Maintena) (Last Updated: Jan 6, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Abilify Maintena
Manufacturer:
Otsuka Canada Pharmaceutical Inc. & Lundbeck Canada Inc.
Submission Type:
Initial
Indications:

Schizophrenia